Advances in Cancer Research

Erscheinungsjahr 2026
ISBN: 978-0-443-43238-5
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm

Advances in Cancer Research, Volume 172 in this ongoing series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including Memantine and its Analogs: Potential Applications in Cancer Therapy, The role of epigenetic modifications in mediating cancer health disparities, Tumor Associated Macrophages: Ontogeny, Plasticity, Spatial Ecosystems, and Therapeutic Targeting, Recognizing the significance of cancer-nerve crosstalk in advanced prostate cancer, and much more.

Autoren/Hrsg.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Immunologie
• Naturwissenschaften Biowissenschaften Biowissenschaften Genetik und Genomik (nichtmedizinisch)
• Naturwissenschaften Biowissenschaften Zellbiologie
• Naturwissenschaften Biowissenschaften Mikrobiologie

Inhaltsverzeichnis

1. Memantine and its Analogs: Potential Applications in Cancer Therapy
Piyali Dasgupta, Monica Valentovic, Kathleen Brown, Amanda Sugrue, Javan Christain, Kaitlyn Conley, Kushal Modi, Christopher Bender, Sarah McGuffey, Sadia Akter, Todd Gress, Rebecca Wolfer, Brian Antoniano, Gregory Cummings, Krista Denning and Sarah Miles
2. The role of epigenetic modifications in mediating cancer health disparities
Steven Grant, Dhanvin Yajaman, Keri Maher and Dhanush Bearelly
3. Tumor Associated Macrophages: Ontogeny, Plasticity, Spatial Ecosystems, and Therapeutic Targeting
Atif Elnaggar and Abdelrahman Elnaggar
4. TBD
Paul B. Fisher
5. TBD
Michael D. Henry
6. Recognizing the significance of cancer-nerve crosstalk in advanced prostate cancer
Samikshan Dutta

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.